AstraZeneca, facing investigations in China and challenges with its UK operations, had a financially successful year. Despite controversies, the company aims for future growth with new medicines and investments. The CEO's high pay raises concerns among shareholders and experts.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing